Search results for "COLON"

showing 10 items of 2038 documents

Hepatic arterial infusion of gemcitabine-oxaliplatin in a large metastasis from colon cancer

2010

International audience; Hepatic arterial infusion (HAI) of chemotherapy can be performed in cases of liver-confined metastatic disease, resulting in increased local drug concentrations. Here we report the case of a 61-year-old man who presented with an isolated large unresectable liver metastasis of colon cancer after failure of surgery and multiple administration of systemic chemotherapy. The patient was treated with a combination of gemcitabine and oxaliplatin using HAI. The tolerance was excellent and a radiological complete response was obtained after 8 cycles of HAI. The rationale for the use of gemcitabine and oxaliplatin as well as that for the combination of the 2 drugs is discussed…

OncologyMale[SDV.MHEP.CHI] Life Sciences [q-bio]/Human health and pathology/SurgeryOrganoplatinum CompoundsColorectal cancermedicine.medical_treatmentCase ReportDeoxycytidineMetastasischemistry.chemical_compound0302 clinical medicineHepatic ArteryAntineoplastic Combined Chemotherapy Protocols[ SDV.MHEP.CHI ] Life Sciences [q-bio]/Human health and pathology/Surgery0303 health sciencesLiver NeoplasmsGastroenterologyvirus diseasesGeneral MedicineMiddle AgedMagnetic Resonance Imaging3. Good healthOxaliplatinTreatment Outcome030220 oncology & carcinogenesisColonic NeoplasmsCatheter AblationAdenocarcinomaDeoxycytidinemedicine.drugmedicine.medical_specialtyanimal structures[SDV.MHEP.CHI]Life Sciences [q-bio]/Human health and pathology/SurgeryAdenocarcinoma03 medical and health sciencesHepatic arterial infusionInternal medicinemedicineHumansInfusions Intra-Arterial030304 developmental biologyChemotherapybusiness.industrymedicine.diseaseGemcitabineGemcitabineOxaliplatinchemistrybusinessTomography X-Ray Computed
researchProduct

Epidemiology and prognosis of synchronous and metachronous colon cancer metastases: a French population-based study.

2014

Epidemiological data on synchronous and metachronous metastatic colon cancer are scarce. We assessed epidemiological characteristics and survival in synchronous and metachronous metastatic colon cancer in a French population.Our study included 932 cases of metastatic colon cancer diagnosed in 1999-2010 and registered in a population-based cancer registry; 758 were synchronous colon metastases and 174 metachronous metastases from resected primary colon cancers diagnosed in 1999-2005. Univariate relative survival was calculated and a multivariate model with proportional hazard applied to net survival by interval was used.Mean age at diagnosis was 71.1 years for patients with metachronous meta…

OncologyMalemedicine.medical_specialtyColorectal cancermedicine.medical_treatmentPopulationNeoplasms Multiple PrimaryMetachronous metastasisRisk FactorsInternal medicineEpidemiologyMedicineHumanseducationAgedRetrospective StudiesChemotherapyeducation.field_of_studyHepatologyRelative survivalbusiness.industryGastroenterologyNeoplasms Second PrimaryOdds ratiomedicine.diseasePrognosisCancer registrySurvival RatePopulation SurveillanceColonic NeoplasmsFemaleFranceMorbiditybusinessFollow-Up StudiesDigestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
researchProduct

Prognostic Impact of pT Stage and Peritoneal Invasion in Locally Advanced Colon Cancer

2019

BACKGROUND: TNM stage has been identified as an independent variable for local recurrence and survival after colon cancer resection. It is still unclear whether peritoneal invasion (pT4a) is a risk factor for adverse oncologic outcome or whether these patients have better results compared with contiguous organs infiltration (pT4b), independent from nodal status (pN). OBJECTIVE: The purpose of this study was to analyze whether peritoneal invasion is an independent risk factor for worse oncologic outcome after curative colon cancer resection. DESIGN: This was a retrospective analysis with multivariate regression of a prospective database, according to Strengthening the Reporting of Observatio…

OncologyMalemedicine.medical_specialtySurvivalColorectal cancermedicine.medical_treatmentLocally advancedT stageLocally advanced colon cancer03 medical and health sciences0302 clinical medicineRisk FactorsInternal medicinemedicineColon cancer resectionHumansNeoplasm InvasivenessRisk factorStage (cooking)Survival rateColectomyPeritoneal NeoplasmsColectomyAgedNeoplasm StagingRetrospective StudiesCarcinomatosisTumor-node-metastasisbusiness.industryGastroenterologyRetrospective cohort studyGeneral MedicineMiddle Agedmedicine.diseasePrognosisColon cancerSurvival RateTreatment Outcome030220 oncology & carcinogenesisColonic Neoplasms030211 gastroenterology & hepatologyFemaleNeoplasm Recurrence Localbusiness
researchProduct

Update on capecitabine alone and in combination regimens in colorectal cancer patients

2010

Capecitabine is an orally administered fluoropyrimidine carbamate which has been developed as a prodrug of 5-FU with the goal to improve its tolerability and intratumoral drug concentration. The review aims to provide an evidence-based update of clinical trials investigating the clinical efficacy, adverse-event profile, dosage and administration of this drug, alone or in combination with conventional chemotherapeutics and/or new target-oriented drugs, in the management of colorectal cancer patients. © 2010 Elsevier Ltd.

OncologyOrganoplatinum CompoundsOxaloacetatesSettore MED/06 - Oncologia MedicaColorectal cancerLeucovorinCetuximabAdministration OralDeoxycytidineAntineoplastic Combined Chemotherapy ProtocolsProdrugsAdjuvantCetuximabAntibodies MonoclonalGeneral MedicineNeoadjuvant TherapyOxaliplatinBevacizumabColorectal carcinomacolon cancerOncologyTolerabilityChemotherapy AdjuvantMetastaticFluorouracilNeoadjuvantColorectal Neoplasmsmedicine.drugDiarrheaAntimetabolites Antineoplasticmedicine.medical_specialtyBevacizumabAntibodies Monoclonal HumanizedIrinotecanDrug Administration ScheduleAdjuvant; Bevacizumab; Capecitabine; Cetuximab; Colorectal carcinoma; Irinotecan; Metastatic; Neoadjuvant; Oxaliplatin; Radiotherapy; Oncology; Radiology Nuclear Medicine and ImagingCapecitabineInternal medicinemedicineHumansRadiology Nuclear Medicine and imagingCapecitabineRadiotherapybusiness.industrymedicine.diseaseOxaliplatinClinical trialIrinotecanCamptothecinRadiotherapy AdjuvantbusinessCancer Treatment Reviews
researchProduct

Peritoneal invasion and metachronous peritoneal metastases after colon cancer surgery: The role of homogeneous, reliable assessment and confounders

2021

OncologyPeritoneal metastasismedicine.medical_specialtyColonic NeoplasmStagingColorectal cancerbusiness.industryConfoundingGeneral Medicinemedicine.diseaseColon cancerPeritoneal invasionOncologyTumour cellHomogeneousInternal medicinemedicineLocal recurrencePeritoneal metastasiSurgeryPeritoneumbusinessPeritoneal NeoplasmsHuman
researchProduct

Familial colorectal cancer risk: ESMO Clinical Practice Guidelines.

2010

OncologyRiskmedicine.medical_specialtyHeterozygoteColorectal cancermedicine.medical_treatmentColonoscopyAntineoplastic AgentsPenetranceGastroenterologyDNA Mismatch RepairInternal medicinemedicinePrevalenceHumansGenetic TestingRisk factorSigmoidoscopyColectomyColectomyGenetic testingRandomized Controlled Trials as Topicmedicine.diagnostic_testProctocolectomybusiness.industryIncidenceProctocolectomy RestorativeCancerSigmoidoscopyHematologyColonoscopymedicine.diseaseColorectal Neoplasms Hereditary NonpolyposisCombined Modality TherapyEuropeOncologybusinessFollow-Up StudiesAnnals of oncology : official journal of the European Society for Medical Oncology
researchProduct

Dilemma in metastatic colorectal cancer: VEGF versus EGRF targeting

2013

Abstract: The modern approach for metastatic colorectal cancer (mCRC) patients is based on the identification of oncogenic pathways, which could be targeted by specific molecules. Vascular endothelial growth factor (VEGF)- and epithelial growth factor receptor (EGFR)-related pathways represent the most important biological mechanisms for cancer development and progression. However, the most significant results by VEGF and EGFR targeting could be achieved through the combination of these drugs with standard chemotherapeutic regimens. These strategies aim to improve the resectability of liver and lung metastases. For those patients who cannot be eligible for metastases resection, a 'continuum…

OncologyVascular Endothelial Growth Factor Amedicine.medical_specialtyColorectal cancerSettore MED/06 - Oncologia MedicaVEGF receptorsClinical BiochemistryResectionchemistry.chemical_compoundGrowth factor receptorInternal medicineDrug DiscoveryMedicineHumansTarget therapyContinuum of carePharmacologybiologybusiness.industryPharmacology. Therapycolon cancer EGFR target therapies VEGFmedicine.diseaseVascular endothelial growth factorErbB Receptorschemistrybiology.proteinMolecular MedicineCancer developmentbusinessColorectal Neoplasms
researchProduct

G-CSF (filgrastim) treatment for amyotrophic lateral sclerosis: protocol for a phase II randomised, double-blind, placebo-controlled, parallel group,…

2020

IntroductionAmyotrophic lateral sclerosis (ALS) is a fatal progressive neurological disorder characterised by a selective degeneration of motor neurons (MNs). Stem cell transplantation is considered as a promising strategy in neurological disorders therapy and the possibility of inducing bone marrow cells (BMCs) to circulate in the peripheral blood is suggested to investigate stem cells migration in degenerated ALS nerve tissues where potentially repair MN damage. Granulocyte-colony stimulating factor (G-CSF) is a growth factor which stimulates haematopoietic progenitor cells, mobilises BMCs into injured brain and it is itself a neurotrophic factor for MN. G-CSF safety in humans has been de…

Oncologyamyotrophic lateral sclerosismedicine.medical_specialtyFilgrastimFilgrastimPlacebocGSF ALS Clinical triallaw.inventionrandomised clinical trialClinical Trials Phase II as TopicDouble-Blind MethodRandomized controlled triallawInternal medicinemedicineHumansMulticenter Studies as Topic1506Amyotrophic lateral sclerosisRandomized Controlled Trials as Topicbusiness.industryRGeneral Medicineamyotrophic lateral sclerosis; GCS-F; haematopoietic stem cells; randomised clinical trialmedicine.diseaseGranulocyte colony-stimulating factorTransplantationClinical trialGCS-FNeurologyItalyTolerabilityQuality of Life1713MedicineSettore MED/26 - Neurologiabusinesshaematopoietic stem cellsmedicine.drugBMJ Open
researchProduct

33 EFFECT OF miR-21, miR-182 AND let-7i ON TSP-1 EXPRESSION IN COLON CANCER CELL LINE

2010

Oncologybusiness.industryColon cancer cell lineCancer researchMedicineRadiology Nuclear Medicine and imagingGeneral MedicinebusinessCancer Treatment Reviews
researchProduct

Effect of Treatment with rhGM-CSF and Low-Dose Cytosine Arabinoside on Leukemic Blast Cells in Patients with Myelodysplastic Syndromes

1990

Treatment of patients having myelodysplastic a syndromes (MDS) with approaches such as differentiation induction, single cytostatic agents or supportive care only has, up to now, been rather unsuccessful. Aggressive chemotherapy followed by bone marrow transplantation is only suitable for a very small proportion of patients. Thus, there is a need for new therapeutic alternatives.

Oncologymedicine.medical_specialtyAcute myeloblastic leukemiabusiness.industryCellular differentiationmedicine.medical_treatmentMyelodysplastic syndromesmedicine.diseaseLeukemiaGranulocyte macrophage colony-stimulating factorCytokineInternal medicinePrecursor cellImmunologyCytarabineMedicinebusinessmedicine.drug
researchProduct